A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3–4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with serum C-telopeptide (CTx) levels ≤600 ng/L af...

詳細記述

保存先:
書誌詳細
主要な著者: Addison, Christina L., Bouganim, Nathaniel, Hilton, John, Vandermeer, Lisa, Dent, Susan, Amir, Eitan, Hopkins, Sean, Kuchuk, Iryna, Segal, Roanne, Song, Xinni, Gertler, Stan, Mazzarello, Sasha, Dranitsaris, George, Ooi, Daylily, Pond, Gregory, Clemons, Mark
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2014
主題:
Clinical Trial
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3962742/
https://ncbi.nlm.nih.gov/pubmed/24638849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-2906-x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料